ZevAryehWainbergMD

Oncology • Santa Monica, CA

Professor, Medicine, UCLA School of Medicine

Join to view full profile

Dr. Wainberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wainberg's full profile

Already have an account?

Office
2020 Santa Monica Blvd
Ste 600
Santa Monica, CA 90404
Phone+1 310-829-5471

Fax+1 310-829-6192

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2000 - 2003
Tel Aviv University SacklerClass of 2000

Certifications & Licensure

CA State Medical License 2003 - 2025
NY State Medical License 2001 - 2003
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Start of enrollment: 2007 Dec 01
Completed
Phase 2
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer Start of enrollment: 2009 Sep 01
Completed
Phase 2
Safety Study of PLX108-01 in Patients With Solid Tumors Start of enrollment: 2009 Oct 01
Completed
Phase 1
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Start of enrollment: 2011 Jan 03
Completed
Phase 1
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors Start of enrollment: 2012 Nov 27
Terminated
Phase 1, Phase 2
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer Start of enrollment: 2012 Nov 23
Completed
Phase 2
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 1
Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors Start of enrollment: 2013 Aug 01
Terminated
Phase 1
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors Start of enrollment: 2013 Nov 19
Completed
Phase 1, Phase 2
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2014 Jun 12
Completed
Phase 1
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Start of enrollment: 2016 Feb 19
Completed
Phase 1
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer Start of enrollment: 2019 Jul 24
Active, not recruiting
Early Phase 1
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors Start of enrollment: 2020 Feb 20
Terminated
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

49 citations
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phas...
Sun Young Rha, Do-Youn Oh, Patricio Yañez, Yuxian Bai, Min-Hee Ryu
The Lancet. Oncology. 2023-11-01
624 citations
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Ph...
Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, Charles S. Fuchs, Lucjan Wyrwicz
JAMA Oncology. 2020-10-01
3 citations
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).
Elena Garralda, Do Youn Oh, Antoine Italiano, Philippe L Bedard, Jean-Pierre Delord
Journal of Clinical Pharmacology. 2024-05-01

Journal Articles

Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy Alone for Patients with First-Line, Advanced Gastric Cancer
Al Benson, Zev A Wainberg, JAMA Oncology

Lectures

First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC).
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase ...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) can...
2019 ASCO Annual Meeting - 6/1/2019
Results from a phase I study of andecaliximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin ...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Join now to see all

Press Mentions

NALIRIFOX Changes Care in Pancreatic Cancer: Here’s HowFebruary 16th, 2023
Four-Drug Chemotherapy Regimen Shows Promise for Advanced Pancreatic CancerJanuary 25th, 2023
NALIRIFOX: A New Reference Standard for Metastatic Pancreatic AdenocarcinomaJanuary 23rd, 2023
Join now to see all

ZevAryehWainbergMD

Dr. Wainberg is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.